Management of Women Who Have a Genetic Predisposition for Breast Cancer

Surgical Clinics of North America

Volumn 88, Issue 4, 2008, Pages 845-861

  Jatoi, Ismail ^a   Anderson, William F ^b  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; PLACEBO; RALOXIFENE; TAMOXIFEN;

BREAST CANCER; BREAST SELF EXAMINATION; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; ENDOMETRIUM CANCER; FAMILIAL CANCER; FAMILY HISTORY; GENE MUTATION; GENETIC ANALYSIS; GENETIC PREDISPOSITION; GENETIC RISK; HUMAN; MAMMOGRAPHY; MASTECTOMY; OVARY CANCER; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM; UTERUS CANCER;

BREAST NEOPLASMS; FEMALE; GENE THERAPY; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; MASTECTOMY;

EID: 48049113484     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.suc.2008.04.007     Document Type: Review

References (72)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 2 (2008) 71-96
2. Hankinson S.E., Colditz G.A., and Willett W.C. Towards an integrated model for breast cancer etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res 6 5 (2004) 213-218
3. van de Vijver M.J. The pathology of familial breast cancer: the pre-BRCA1/BRCA2 era: historical perspectives. Breast Cancer Res 1 1 (1999) 27-30
4. Anderson K., et al. Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med 144 6 (2006) 397-406
5. Thull D.L., and Vogel V.G. Recognition and management of hereditary breast cancer syndromes. Oncologist 9 1 (2004) 13-24
6. Robson M., and Offit K. Clinical practice. Management of an inherited predisposition to breast cancer. N Engl J Med 357 2 (2007) 154-162
7. Emery J., Lucassen A., and Murphy M. Common hereditary cancers and implications for primary care. Lancet 358 9275 (2001) 56-63
8. Rubinstein W.S. Surgical management of BRCA1 and BRCA2 carriers: bitter choices slightly sweetened. J Clin Oncol 23 31 (2005) 7772-7774
9. Wooster R., Neuhausen S.L., Mangion J., et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 265 5181 (1994) 2088-2090
10. Hall J.M., Lee M.K., and Newman B. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 250 4988 (1990) 1684-1689
11. Narod S.A., and Foulkes W.D. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 4 9 (2004) 665-676
12. Iau P.T., Macmillan R.D., and Blamey R.W. Germ line mutations associated with breast cancer susceptibility. Eur J Cancer 37 3 (2001) 300-321
13. U.S. Protective Services Task Force. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 143 5 (2005) 355-361
14. Frank T.S., Deffenbaugh A.M., Reid J.E., et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol 20 6 (2002) 1480-1490
15. Miki Y., Swensen J., Shattuck-Eidens D., et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266 5182 (1994) 66-71
16. Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 378 6559 (1995) 789-792
17. Chen S., and Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 25 11 (2007) 1329-1333
18. Levy-Lahad E., and Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 96 1 (2007) 11-15
19. Chen S., Iversen E.S., Friebel T., et al. Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24 6 (2006) 863-871
20. Ferla R., Calo Y., Cascio S., et al. Founder mutations in BRCA1 and BRCA2 genes. Ann Oncol 18 Suppl 6 (2007) vi93-vi98
21. Narod S.A., and Offit K. Prevention and management of hereditary breast cancer. J Clin Oncol 23 8 (2005) 1656-1663
22. Antoniou A.C., Pharoah P.D., Narod S., et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42 7 (2005) 602-603
23. Tai Y.C., Domchek S., Parmigiani G., et al. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers. J Natl Cancer Inst 99 23 (2007) 1811-1814
24. Garber J.E., and Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 23 2 (2005) 276-292
25. American Society of Clinical Oncology. Policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 21 12 (2003) 2397-2406
26. Nelson H.D., Huffman L.H., Fu R., et al. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 143 5 (2005) 362-379
27. Berliner J.L., and Fay A.M. Risk assessment and genetic counseling for hereditary breast and ovarian cancer: recommendations of the National Society of Genetic Counselors. J Genet Couns 16 3 (2007) 241-260
28. Rebbeck T.R., Lynch H.T., Neuhausen S.L., et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 346 21 (2002) 1616-1622
29. Taylor M.R. Genetic testing for inherited breast and ovarian cancer syndromes: important concepts for the primary care physician. Postgrad Med J 77 903 (2001) 11-15
30. Jatoi I., and Anderson W.F. Cancer screening. Curr Probl Surg 42 9 (2005) 620-682
31. Jatoi I. Breast cancer screening. Am J Surg 177 6 (1999) 518-524
32. Jatoi I. Screening clinical breast examination. Surg Clin North Am 83 4 (2003) 789-801
33. Moss S.M., Cuckle H., Evans A., et al. Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial. Lancet 368 9552 (2006) 2053-2060
34. Semiglazov V.F., Moisenko V.M., Manikhas A.G., et al. Interim results of a prospective randomized study of self-examination for early detection of breast cancer (Russia/St.Petersburg/WHO). Vopr Onkol 45 3 (1999) 265-271 [in Russian]
35. Thomas D.B., Gao D.L., Ray R.M., et al. Randomized trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst 94 19 (2002) 1445-1457
36. Liberman L. Breast cancer screening with MRI-what are the data for patients at high risk?. N Engl J Med 351 5 (2004) 497-500
37. Hendrick R.E., Smith R.A., Rutledge III J.H., et al. Benefit of screening mammography in women aged 40-49: a new meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr 22 (1997) 87-92
38. Kerlikowske K., Grady D., Rubin S.M., et al. Efficacy of screening mammography. A meta-analysis. JAMA 273 2 (1995) 149-154
39. Vaidya J.S., and Baum M. Benefits and risks of screening mammography in women with BRCA1 and BRCA2 mutations. JAMA 278 4 (1997) 290
40. Narod S.A., Lubinski J., Ghadirian P., et al. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Lancet Oncol 7 5 (2006) 402-406
41. Goldfrank D., Chuai S., Bernstein J.L., et al. Effect of mammography on breast cancer risk in women with mutations in BRCA1 or BRCA2. Cancer Epidemiol Biomarkers Prev 15 11 (2006) 2311-2313
42. Barton M.B., Harris R., and Fletcher S.W. The rational clinical examination. Does this patient have breast cancer? The screening clinical breast examination: should it be done? How?. JAMA 282 13 (1999) 1270-1280
43. Kriege M., Brekelmans C.T., Boetes C., et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351 5 (2004) 427-437
44. Saslow D., Boetes C., Burke W., et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 57 2 (2007) 75-89
45. Anderiesz C., and Quinn M.A. Screening for ovarian cancer. Med J Aust 178 12 (2003) 655-656
46. Stirling D., Evans D.G., Pichert G., et al. Screening for familial ovarian cancer: failure of current protocols to detect ovarian cancer at an early stage according to the international Federation of gynecology and obstetrics system. J Clin Oncol 23 24 (2005) 5588-5596
47. Guillem J.G., Wood W.C., Moley J.F., et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 24 28 (2006) 4642-4660
48. Hartmann L.C., Schaid D.J., Woods J.E., et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med 340 2 (1999) 77-84
49. Meijers-Heijboer H., van Geel B., van Putten W.L., et al. Breast cancer after prophylactic bilateral mastectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 345 3 (2001) 159-164
50. Rebbeck T.R., Friebel T., Lynch H.T., et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol 22 6 (2004) 1055-1062
51. Hartmann L.C., Sellars T.A., Schaid D.J., et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 93 21 (2001) 1633-1637
52. Ueda S., Tamaki Y., Yano K., et al. Cosmetic outcome and patient satisfaction after skin-sparing mastectomy for breast cancer with immediate reconstruction of the breast. Surgery 143 3 (2008) 414-425
53. Carlson G.W. Breast reconstruction. Surgical options and patient selection. Cancer 74 Suppl 1 (1994) 436-439
54. Bostwick III J., and Carlson G.W. Reconstruction of the breast. Surg Oncol Clin N Am 6 1 (1997) 71-89
55. Kauff N.D., Satagopan J.M., Robson M.E., et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 346 21 (2002) 1609-1615
56. Baum M., Brinkley D.M., Dossett J.A., et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 2 8347 (1983) 450
57. Cuzick J., and Baum M. Tamoxifen and contralateral breast cancer. Lancet 2 8449 (1985) 282
58. Powles T.J., Jones A.L., Ashley J.E., et al. The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31 1 (1994) 73-82
59. Fisher B., Jones A.L., Ashley J.E., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90 18 (1998) 1371-1388
60. Veronesi U., Maisonneuve P., Sacchini V., et al. Tamoxifen for breast cancer among hysterectomised women. Lancet 359 9312 (2002) 1122-1124
61. Cuzick J., Forbes J., Edwards R., et al. First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial. Lancet 360 9336 (2002) 817-824
62. Cuzick J., Powles T., Veronesi U., et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 361 9354 (2003) 296-300
63. King M.C., Wieand S., Hale K., et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA 286 18 (2001) 2251-2256
64. Narod S.A., Brunet J.S., Ghadirian P., et al. Tamoxifen and risk of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study. Hereditary Breast Cancer Clinical Study Group. Lancet 356 9245 (2000) 1876-1881
65. Rebbeck T.R., Levin A.M., Eisen A., et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 91 17 (1999) 1475-1479
66. Fisher B., Constantino J.P., Wickerhan D.L., et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 97 22 (2005) 1652-1662
67. Vogel V.G., Constantino J.P., Wickerhan D.L., et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295 23 (2006) 2727-2741
68. Anderson W.F., Brawley O.W., and Chang S. Oophorectomy in carriers of BRCA mutations. N Engl J Med 347 (2002) 1037-1040
69. Domchek S.M., Armstrong K., and Weber B.L. Clinical management of BRCA1 and BRCA2 mutation carriers. Nat Clin Pract Oncol 3 1 (2006) 2-3
70. Pierce L.J., Strawderman M., Narod S.A., et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 18 19 (2000) 3360-3369
71. Metcalfe K.A., Lubinski J., Ghadirian P., et al. Predictors of contralateral prophylactic mastectomy in women with a BRCA1 or BRCA2 mutation: the Hereditary Breast Cancer Clinical Study Group. J Clin Oncol 26 7 (2008) 1093-1097
72. Recht A., Edge S.B., Solin L.J., et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19 5 (2001) 1539-1569